Form 4: Annexon Director and 10% Owner Muneer Satter Granted 55,000 Stock Options

Muneer A. Satter, a Director and 10% Owner of Annexon, Inc., was granted 55,000 stock options with an exercise price of $2.55, vesting on the first anniversary of the grant date or the next annual meeting.

Summary

• Muneer A. Satter, a Director and 10% Owner of Annexon, Inc. (ANNX), acquired 55,000 stock options.
• The stock options have an exercise price of $2.55 per share.
• The transaction date for the option grant was June 5, 2025.
• The options vest 100% on the earlier of June 5, 2026 (the first anniversary of the grant date) or the next Annual Meeting following June 5, 2025.
• Vesting is contingent upon Mr. Satter's continuous service as a director until the vesting date.
• The options have an expiration date of June 5, 2035.
• Following this transaction, Mr. Satter directly beneficially owns 55,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director and 10% owner is generally a positive signal as it aligns their interests with the company's long-term performance and encourages continued commitment. It's a routine compensation event for a director.

Positives

• The grant of stock options to a director and 10% owner aligns their interests with long-term shareholder value.
• The vesting schedule encourages continued service and commitment from a significant stakeholder.

Risks

• The vesting of the options is subject to Muneer A. Satter's continuous service as a director, meaning the options could be forfeited if service ceases before the vesting date.
• The value of the options is dependent on Annexon, Inc.'s common stock price exceeding the exercise price of $2.55 per share.

Future Outlook

The grant of stock options with a future vesting schedule indicates an expectation of continued service from the director and aligns their future financial incentives with the company's performance.

Industry Context

This Form 4 filing reflects a standard practice of granting equity compensation to directors in the biotechnology or pharmaceutical industry to incentivize long-term commitment and align interests with shareholders. Such grants are common for directors, especially those who are also significant owners, to ensure their continued engagement and oversight.

Comparison to Industry Standards

• Granting stock options to directors is a common compensation practice across industries, including biotechnology.
• The vesting schedule (100% on first anniversary or next annual meeting) is a typical structure for director equity grants, promoting retention and aligning interests over a reasonable timeframe.
• A direct quantitative comparison of the specific exercise price ($2.55) and the number of options (55,000) against similar grants at peer companies (e.g., Biogen, Amgen, Gilead Sciences, or smaller biotech firms) would be required to assess if it's within industry norms for director compensation, which is not possible from this document alone.

Related Party Transactions

• The acquisition of stock options by Muneer A. Satter, a Director and 10% Owner, constitutes a related party transaction as it involves a significant stakeholder and company insider.

Stakeholder Impact

• Shareholders: The grant of options to a director and 10% owner aligns their interests with shareholders, potentially leading to better long-term performance. However, future exercise of options could lead to minor dilution.

Next Steps

• Muneer A. Satter's continuous service as a director until the vesting date.
• The options will become exercisable on the earlier of June 5, 2026, or the next Annual Meeting following June 5, 2025.

Key Dates

Recommendation

Keywords

Annexon Inc., ANNX, Form 4, SEC filing, stock options, beneficial ownership, director compensation, insider transaction, equity grant, Muneer A. Satter